Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis.
- Resource Type
- Article
- Authors
- Karakurt Eryılmaz, Melek; Karaağaç, Mustafa
- Source
- Journal of Oncology Pharmacy Practice. Dec2019, Vol. 25 Issue 8, p2031-2034. 4p. 1 Color Photograph.
- Subject
- *PREDNISONE
*ANDROGENS
*COMBINATION drug therapy
*METASTASIS
*PROSTATE tumors
*ABIRATERONE acetate
*CYTOCHROME P-450
*CHEMICAL inhibitors
- Language
- ISSN
- 1078-1552
Abiraterone is an oral inhibitor of cytochrome P450 (17alpha)-hydroxylase/17,20 lyase (CYP17) complex critical to androgen production. Abiraterone in combination with prednisone is currently FDA approved for use in men with metastatic castration-resistant prostate cancer, both in the pre- and post-chemotherapy settings. This article discusses the treatment with abiraterone in a patient with metastatic castration-resistant prostate cancer on hemodialysis. [ABSTRACT FROM AUTHOR]